Wilson Disease Clinical Trial
Official title:
Registro de Enfermedad de Wilson en España
The main objective and purpose of the Registry is to know the current status of Wilson Disease in Spain. As secondary objectives, the prevalence and incidence of the disease will be analysed. Likewise, the analysis aims to define future areas of interest in its pathogenesis, diagnosis, natural history, follow-up, prognosis and treatment. Improving knowledge at a national level can help to design screening strategies and improve diagnostic circuits.
| Status | Recruiting |
| Enrollment | 600 |
| Est. completion date | December 2030 |
| Est. primary completion date | December 2030 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients with a confirmed Wilson Disease diagnosis Exclusion Criteria: - Refusal to sign the informed consent for the study |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Hospital Clinic | Barcelona |
| Lead Sponsor | Collaborator |
|---|---|
| Asociación Española para el Estudio del Hígado |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | To define future areas of interest in Wilson Disease | To define future areas of interest in the disease pathogenesis, diagnosis, natural history, follow-up, prognosis and treatment | 2025 | |
| Primary | To know the current status of Wilson Disease in Spain | 2025 | ||
| Secondary | To analyse the prevalence of Wilson Disease in Spain | 2025 | ||
| Secondary | To analyse the incidence of Wilson Disease in Spain | 2025 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04573309 -
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
|
Phase 2 | |
| Completed |
NCT03539952 -
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04884815 -
Study of UX701 Gene Transfer for the Treatment of Wilson Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03659331 -
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
|
N/A | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
| Terminated |
NCT05047523 -
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
|
Phase 3 | |
| Completed |
NCT04526210 -
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
|
Phase 1 | |
| Completed |
NCT00004338 -
Study of Zinc for Wilson Disease
|
Phase 4 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Completed |
NCT02273596 -
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
|
Phase 2 | |
| Completed |
NCT02763215 -
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
|
||
| Recruiting |
NCT05444127 -
Oral Health and Wilson's Disease: SOMAWI
|
||
| Completed |
NCT04408300 -
Study of Retinal Vascular Parameters in Patients With Wilson's Disease
|
N/A | |
| Active, not recruiting |
NCT05783687 -
Real World Evidence Study in Subjects With Wilson's Disease
|
||
| Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
| Completed |
NCT03867526 -
Establishment of Human Cellular Disease Models for Wilson Disease
|
||
| Enrolling by invitation |
NCT03589820 -
Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure
|
N/A | |
| Completed |
NCT04526197 -
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
|
Phase 1 | |
| Not yet recruiting |
NCT06430359 -
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
|